## IAP7 Rec'd PCT/PTO 3 0 DEC 2005

Express Mail Label No.	Dated:	
		Docket No.: 098

Docket No.: 09859/0203521-US0

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Takao Nakajima et al.

Application No.: 10/554,254

Confirmation No.: N/A

Filed: October 24, 2005

Art Unit: N/A

For: FUSED PYRIMIDINE DERIVATIVES

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

Application No.: 10/554,254 2 Docket No.: 09859/0203521-US0

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the Specification and in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: December 30, 2005

Respectfully submitted,

12900 EARLESON

Louis | Delluidice

Louis J. DelJuidice

Registration No.: 47,522

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7712

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	Substitute for form 1449A/B/PTO		Complete if Known		
				Application Number	10/554,254
IN	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	October 24, 2005
S				First Named Inventor	Takao Nakajima
(Use as many sheets as necessary)				Art Unit	N/A
			necessary)	Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	09859/0203521-US0

	U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	AA**	US-5,270,316	12-14-1993			
	AB**	US-6,489,331B1	12-03-2002			
	AC**	US-2003/0176698A1	09-18-2003			
	AD**	US-2002/0111333A1	08-15-2002			

		FOREI	GN PATENT D	OCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵
	ВА	EP-0884318A1	12-16-1998			Г
	BB	JP10-158267	06-16-1998			
	BC	EP-0390111B1	09-14-1994			Г
	BD	WO2004/011469A1	02-05-2004			Г
	BE	WO03/104804A1	12-18-2003			
	BF	WO03/097862A1	11-27-2003			
	BG	WO03/097064A1	11-27-2003			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
	CA	Communication to the Editor, Journal of Medicinal Chemistry, 1992, Vol. 35, No. 19, pp. 3578-3581			
	СВ	FUMIO SUZUKI, et al., Adenosin A1 Antagonist. 3. Structure-Activity Relationships on Amelioration Against Scopolamine- orN6-((R)-Phenylisopropyl)adenosine-Induced Cognitive Disturbance, Journal of Medicinal Chemistry, 1993, 36, pp. 2508-2518.			
	СС	TEMPLE D.L. JR., et al., Substituted 6,7-Dihydroimidazo[1,2-a]purin-9 (4H)-ones, Journal of Medicinal Chemistry, 1980, 23, pp. 1188-1198.			
	CD	HIROYUKI SAWANISHI, et al., Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed Purines, Journal of Medicinal Chemistry, 1997, 40, pp. 3248-3253			
	CE	International Search Report for PCT/JP2004/005890 mailed August 24, 2004.			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

{W:\098	Date
5010203	Considered

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.